Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (75)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Öberg, K.
Right arrow Articles by Wiedenmann, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Öberg, K.
Right arrow Articles by Wiedenmann, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:966-973, 2004
© 2004 European Society for Medical Oncology

Original Paper

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

Received 22 December 2003; accepted 27 January 2004

This consensus report gives a detailed description of the use of somatostatin analogs in the management of neuroendocrine tumors of the gastroenteropancreatic system. As background information we have outlined critical aspects of the pathology, the use of tumor markers, a definition of functional and non-functional digestive neuroendocrine tumors, different imaging modalities, surgical considerations, liver embolization and the use of cytotoxic drugs as well as interferon. Included in the report is an overview of somatostatin, somatostatin analogs and its receptor expression in different neuroendocrine tumors. It will also define the binding affinities of different somatostatin analogs to the five different subtypes of somatostatin receptor. We compare the efficacy of octreotide and lanreotide in reducing diarrhea and flushing. Side-effects are described and we provide practical information on somatostatin analog treatment.

K. Öberg1,*, L. Kvols2, M. Caplin3, G. Delle Fave4, W. de Herder5, G. Rindi6, P. Ruszniewski7, E. A. Woltering8 and B. Wiedenmann9

1 Department of Endocrine Oncology, University Hospital, Uppsala, Sweden; 2 University of South Florida, Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 3 Center for Gastroenterology, Royal Free Hospital, London, UK; 4 II School of Medicine, Ospedale Sant, Andrea, Università degli Studi di Roma ‘La Sapienza’, Rome, Italy; 5 Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, the Netherlands; 6 Departimento di Patologica e Medicina di Laboratorio, Sezione di Anatomica, Patologica, Universita degli Studi, Panua, Italy; 7 Hospital Beaujon, Service de Gastroenterologie, Clichy, France; 8 Lousiana University, Health Service Center, New Orleans, LA, USA; 9 Medizinische Klinik M.S., Head of Department, Hepatologie und Gastroenterologie, Berlin, Germany

Key words: gastroenteropancreatic system, lanreotide, neuroendocrine tumors, octreotide, somatostatin, somatostatin analogs, tumor markers, imaging


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al.
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Debono, L.-Q. Hon, N. Bax, A. Blakeborough, and J. Newell-Price
Gluteal Nodules in Patients with Metastatic Midgut Carcinoid Disease Treated with Depot Somatostatin Analogs
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1860 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Asnacios, F. Courbon, P. Rochaix, E. Bauvin, V. Cances-Lauwers, C. Susini, S. Schulz, A. Boneu, R. Guimbaud, and L. Buscail
Indium-111-Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors
J. Clin. Oncol., February 20, 2008; 26(6): 963 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
E. Liapi, J.-F. Geschwind, J. A. Vossen, M. Buijs, C. S. Georgiades, D. A. Bluemke, and I. R. Kamel
Functional MRI Evaluation of Tumor Response in Patients with Neuroendocrine Hepatic Metastasis Treated with Transcatheter Arterial Chemoembolization
Am. J. Roentgenol., January 1, 2008; 190(1): 67 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. H Kulke
Gastrointestinal neuroendocrine tumors: a role for targeted therapies?
Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. H. Jensen, L. Kvols, J. M. McLoughlin, J. M. Lewis, M. D. Alvarado, T. Yeatman, M. Malafa, and D. Shibata
Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors
Ann. Surg. Oncol., February 1, 2007; 14(2): 780 - 785.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
A. D. Levy and L. H. Sobin
From the Archives of the AFIP: Gastrointestinal Carcinoids: Imaging Features with Clinicopathologic Comparison
RadioGraphics, January 1, 2007; 27(1): 237 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G Butturini, R Bettini, E Missiaglia, W Mantovani, I Dalai, P Capelli, M Ferdeghini, P Pederzoli, A Scarpa, and M Falconi
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1213 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Susini and L Buscail
Rationale for the use of somatostatin analogs as antitumor agents
Ann. Onc., December 1, 2006; 17(12): 1733 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E Ferrante, C Pellegrini, S Bondioni, E Peverelli, M Locatelli, P Gelmini, P Luciani, A Peri, G Mantovani, S Bosari, et al.
Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 955 - 962.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Panzuto, M. Di Fonzo, E. Iannicelli, R. Sciuto, C. L. Maini, G. Capurso, M. Milione, M. S. Cattaruzza, M. Falconi, V. David, et al.
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
Ann. Onc., March 1, 2006; 17(3): 461 - 466.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. H. Gunn, J. E. Schwimer, M. Cox, C. T. Anthony, M. S. O'Dorisio, and E. A. Woltering
In Vitro Modeling of the Clinical Interactions Between Octreotide and 111In-Pentetreotide: Is There Evidence of Somatostatin Receptor Downregulation?
J. Nucl. Med., February 1, 2006; 47(2): 354 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M Essand, S Vikman, J Grawe, L Gedda, C Hellberg, K Oberg, T H Totterman, and V Giandomenico
Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1
J. Mol. Endocrinol., December 1, 2005; 35(3): 489 - 501.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.